Ryan Rountree

Ryan Rountree

Company: Nurix Therapeutics

Job title: Senior Director, Preclinical Pharmacology


Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T & NK Cell Mediated Anti-Tumor Response 10:00 am

CBL-B E3 ubiquitin ligase functions as a negative regulator of T cell receptor activation Reporting the discovery of NX-1607, an orally bioavailable CBL-B inhibitor that demonstrates anti-tumor activity in multiple preclinical tumor models NX-1607 triggers rapid NK and T cell infiltration of tumors and shows increased frequency of tumor rejection in combination with anti-PD-1. Our…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.